Audit: QRS - Olive Oil for Health & Longevity

Audit conducted on 03/09/2026 04:57 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values (40–50 mL, 50 mL, split across 2–3 meals), time-to-effect values (3 weeks, 4.8 years, 6–12 weeks), benefit and risk tier items, all 11 monitoring rows, the cadence text and all 5 qualitative items trace to literal ER passages.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The one cautious construction in the source — the oxidised LDL target “No established clinical target exists; track change from the individual’s own baseline” — is carried verbatim (line 807).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication scope qualifiers (“for topical application specifically”, “above 40 mL daily specifically”) and benefit conditionals (“with high-phenolic oil”, “versus refined oil”, “when substituted for other fats”) are all retained at ER strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid Olive Oil” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor appears in any gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no NCT identifiers, no expert names (Magiatis, Melliou, PREDIMED, EUROLIVE are all correctly dropped) and no brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register carried through, including the ER’s “helps when it replaces other fats and works against a person when simply added” framing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and thresholds throughout, with actionable protocol and monitoring cells.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Cells state values and rationale rather than issuing instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives or prescriptions; monitoring rows present ranges and reasons.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cadence is stated as a schedule of measurements, not as an instruction; no “should”, “recommended” or “advised” appears.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person forms anywhere; the oxidised LDL and INR rows use “the individual’s own baseline” / “the individual’s prescribed therapeutic range”.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are load-bearing and spelled out (e.g., “International normalised ratio (INR)”, “High-sensitivity C-reactive protein (hs-CRP)”).
2.8	Information is presented in a concise and very compact manner	🟢	Benefit and risk tiers are semicolon-joined heading-level phrases; interaction items are bare drug-class labels.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Assay thresholds (250 mg/kg phenolics), ApoB and oxidised LDL monitoring, and a research-only assay row all address an optimiser audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Early-harvest assayed high-phenolic oil at 50 mL daily and split dosing across 2–3 meals presume effort and cost tolerance.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges (ApoB < 80, triglycerides < 80, hs-CRP < 1.0) are tighter than conventional cut-offs, consistent with the intended audience.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance and risk tiers foreground the substitution-versus-addition distinction and product-quality unreliability, which are the decision-relevant points for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register throughout (“gingival bleeding”, “atopic dermatitis”, “immunoglobulin-E-mediated”); the plain-language wording in the at-a-glance span is mandated by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All 11 fixed strings verified byte-identical to the template, and all four tier labels appear exactly twice (Benefits and Risks).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 39 template variable names are present; the repeatable marker_#_* and qualitative_item_# spans are expanded to marker_1–11 and qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three non-variable spans (website="evidence_review", website="audit", website="full_review") are unchanged, and a diff of the entire head/CSS block against the template shows only the page_title substitution.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol cell labels (“Standard culinary protocol”, “High-phenolic therapeutic protocol”, “Single versus split dosing”) and all 11 interaction labels reproduce the ER bold labels, with only the parenthetical trimming that item 9.5 permits.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names match the ER biomarker table verbatim; the three time-to-effect labels are drawn from the wording of the ER’s single “Time to effect” bullet rather than invented.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji characters in the file; tiering is conveyed by <strong> labels and the .benefits / .risks CSS palettes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum the other checklist items permit: benefits and risks to heading-level phrases, interactions to bare class labels, and no section is duplicated or extended.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: the comment opens on line 2, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: olive_oil_2026-0903-0223_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0903-0451.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version, with no context-window or other qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: olive_oil_2026-0903-0223_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including the tooling-added git_user: evipedia-1 and git_issue: 5740.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Olive Oil for Health & Longevity - Quick Reference Sheet, with the ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Olive Oil for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/03/2026, correctly derived from qrs_creation_date: 2026-0903-0451.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Five clauses map one-to-one onto the ER Conclusion paragraphs: grade/phenolics, controlled-trial biomarker effect, cohort mortality signal, substitution-versus-addition, product-quality unreliability.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause has a distinct Conclusion sentence as its source; no clause is a synthesis across passages.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “blood-fat” and “blood-vessel measures” replace lipid/endothelial terminology, and “plant compounds” replaces “phenolics”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Only the generic categories “controlled feeding studies” and “population data” appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind in the span.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items come from the “Populations who should avoid Olive Oil” list inside that ER section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER avoid-populations are present, none added: allergy, topical use in infants/atopic dermatitis, bleeding disorder or pre-surgery, and parenteral-nutrition intolerance.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Four <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing clause “— dietary use is unaffected” is stripped from the topical item, and the leading “People with” stems are removed throughout; no dashes remain in any item.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The “within 7 days of scheduled surgery” time window, the “above 40 mL daily” threshold, the “active” severity qualifier on atopic dermatitis and the “documented” qualifiers are all preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names four such populations and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items map to the eleven bulleted interactions in that ER section.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eleven ER interactions are present with no overlap against the four contraindication items.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every item is reduced to the ER’s bold label alone; the Caution/Monitor classification, mechanism, consequence and mitigation sentences are all dropped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All seven parenthetical drug lists are preserved; only “such as gliclazide” is trimmed from the sulfonylurea example, which the item’s shortening allowance permits.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section; all parentheticals are already plain comma-separated lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eleven such interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to bullets in the ER “Therapeutic Protocol” section.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three chosen cells answer how much (standard culinary protocol), what quality (high-phenolic therapeutic protocol) and how to distribute it (single versus split dosing) — the three executable decisions in the section, with the non-actionable bullets (half-life, genetic, sex, age) correctly excluded.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable implementation aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive ER-derived content; no placeholders remain anywhere in the file.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s “Time to effect” bullet names exactly three horizons — blood lipids, inflammatory markers and cardiovascular events — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Blood lipids first (the sole High-tier benefit), then cardiovascular events and inflammatory markers, which are Medium-tier and appear in that relative order in the ER Benefits section.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Values 3 weeks, 4.8 years and 6–12 weeks are ER-literal, and each sub carries the ER’s own qualifying context.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve phrases correspond to the twelve ER benefit sub-headings across the four tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-joined list of the ER sub-headings alone; no Magnitude figures, mechanisms or the ER’s “⚠️ Conflicted” markers are carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four benefit spans.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine phrases correspond to the nine ER risk sub-headings across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier reduces to the ER sub-headings; the Magnitude figures (+2.76 mg/dL, +1.74 cm, 32% aflatoxin prevalence) and the “⚠️ Conflicted” markers are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four risk spans.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER “Monitoring Protocol & Defining Success” biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eleven ER rows are present in ER order — ApoB, LDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, hs-CRP, HbA1c, waist circumference, body weight, INR and oxidised LDL — with targets and “why” text matching the ER columns.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Carries all three ER cadences: lipid panel and hs-CRP at baseline, 12 weeks then every 6–12 months; weight and waist every 4 weeks for 12 weeks; INR at 2 and 4 weeks for warfarin users.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s “Qualitative markers worth tracking alongside the laboratory panel” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five are present and near-verbatim: throat sting, absence of bruising or bleeding, skin condition under topical use, digestive comfort, and satiety/appetite between meals.

Issues 03/09/2026 04:57

Pass rate 100.00%. No issues found.